In the ALINA phase III trial [36], 257 patients with completely resected ALK-translocated stage IB to IIIA NSCLC were randomized to receive oral alectinib 600 mg twice daily for 24 months or adjuvant chemotherapy. Here, ALK is linked to non-small cell lung carcinoma.